These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 12732841)

  • 1. Effect of simultaneous versus staggered dosing on pharmacokinetic interactions of protease inhibitors.
    Washington CB; Flexner C; Sheiner LB; Rosenkranz SL; Segal Y; Aberg JA; Blaschke TF;
    Clin Pharmacol Ther; 2003 May; 73(5):406-16. PubMed ID: 12732841
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Model-based analysis of the pharmacokinetic interactions between ritonavir, nelfinavir, and saquinavir after simultaneous and staggered oral administration.
    Lu JF; Blaschke TF; Flexner C; Rosenkranz SL; Sheiner LB;
    Drug Metab Dispos; 2002 Dec; 30(12):1455-61. PubMed ID: 12433819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir.
    Hsu A; Granneman GR; Cao G; Carothers L; el-Shourbagy T; Baroldi P; Erdman K; Brown F; Sun E; Leonard JM
    Clin Pharmacol Ther; 1998 Apr; 63(4):453-64. PubMed ID: 9585800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic interactions between HIV-1 protease inhibitors in rats: study on combinations of two kinds of HIV-1 protease inhibitors.
    Shibata N; Matsumura Y; Okamoto H; Kawaguchi Y; Ohtani A; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2000 Oct; 52(10):1239-46. PubMed ID: 11092568
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In-vitro and in-vivo pharmacokinetic interactions of amprenavir, an HIV protease inhibitor, with other current HIV protease inhibitors in rats.
    Shibata N; Gao W; Okamoto H; Kishida T; Yoshikawa Y; Takada K
    J Pharm Pharmacol; 2002 Feb; 54(2):221-9. PubMed ID: 11848286
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Saquinavir, nelfinavir and M8 pharmacokinetics following combined saquinavir, ritonavir and nelfinavir administration.
    Stocker H; Herzmann C; Breske A; Kruse G; Berger M; Schulbin H; Hill A; Steinmüller J; Becker M; Arastéh K; Kurowski M
    J Antimicrob Chemother; 2007 Mar; 59(3):560-4. PubMed ID: 17255144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic interaction study of ritonavir-boosted saquinavir in combination with rifabutin in healthy subjects.
    Zhang X; Fettner S; Zwanziger E; Rowell L; Salgo M
    Antimicrob Agents Chemother; 2011 Feb; 55(2):680-7. PubMed ID: 21135186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ritonavir plus saquinavir- and nelfinavir plus saquinavir-containing regimens as salvage therapy in children with human immunodeficiency type 1 infection.
    Hoffmann F; Notheis G; Wintergerst U; Eberle J; Gürtler L; Belohradsky BH
    Pediatr Infect Dis J; 2000 Jan; 19(1):47-51. PubMed ID: 10643850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of saquinavir-ritonavir on cytochrome P450 3A4 activity in healthy volunteers using midazolam as a probe.
    Schmitt C; Hofmann C; Riek M; Patel A; Zwanziger E
    Pharmacotherapy; 2009 Oct; 29(10):1175-81. PubMed ID: 19792991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of human immunodeficiency virus protease inhibitors used in combination with amprenavir.
    Sadler BM; Gillotin C; Lou Y; Eron JJ; Lang W; Haubrich R; Stein DS
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3663-8. PubMed ID: 11709366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults.
    Ribera E; Lopez RM; Diaz M; Pou L; Ruiz L; Falcó V; Crespo M; Azuaje C; Ruiz I; Ocaña I; Clotet B; Pahissa A
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4256-62. PubMed ID: 15504850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular and plasma pharmacokinetics of saquinavir-ritonavir, administered at 1,600/100 milligrams once daily in human immunodeficiency virus-infected patients.
    Ford J; Boffito M; Wildfire A; Hill A; Back D; Khoo S; Nelson M; Moyle G; Gazzard B; Pozniak A
    Antimicrob Agents Chemother; 2004 Jul; 48(7):2388-93. PubMed ID: 15215085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis.
    Ribera E; Azuaje C; Lopez RM; Domingo P; Curran A; Feijoo M; Pou L; Sánchez P; Sambeat MA; Colomer J; Lopez-Colomes JL; Crespo M; Falcó V; Ocaña I; Pahissa A
    J Antimicrob Chemother; 2007 Apr; 59(4):690-7. PubMed ID: 17307771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Low-dose ritonavir moderately enhances nelfinavir exposure.
    Kurowski M; Kaeser B; Sawyer A; Popescu M; Mrozikiewicz A
    Clin Pharmacol Ther; 2002 Aug; 72(2):123-32. PubMed ID: 12189359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of saquinavir/ritonavir on P-glycoprotein activity in healthy volunteers using digoxin as a probe.
    Schmitt C; Kaeser B; Riek M; Bech N; Kreuzer C
    Int J Clin Pharmacol Ther; 2010 Mar; 48(3):192-9. PubMed ID: 20197013
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug-drug interaction study of ketoconazole and ritonavir-boosted saquinavir.
    Kaeser B; Zandt H; Bour F; Zwanziger E; Schmitt C; Zhang X
    Antimicrob Agents Chemother; 2009 Feb; 53(2):609-14. PubMed ID: 19015329
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
    van Heeswijk RP; Veldkamp AI; Mulder JW; Meenhorst PL; Lange JM; Beijnen JH; Hoetelmans RM
    AIDS; 2000 Jun; 14(9):F103-10. PubMed ID: 10894270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of saquinavir hard-gel/ritonavir and atazanavir when combined once daily in HIV Type 1-infected individuals administered different atazanavir doses.
    Boffito M; Maitland D; Dickinson L; Back D; Hill A; Fletcher C; Moyle G; Nelson M; Gazzard B; Pozniak A
    AIDS Res Hum Retroviruses; 2006 Aug; 22(8):749-56. PubMed ID: 16910830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic interactions between sildenafil and saquinavir/ritonavir.
    Muirhead GJ; Wulff MB; Fielding A; Kleinermans D; Buss N
    Br J Clin Pharmacol; 2000 Aug; 50(2):99-107. PubMed ID: 10930961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
    Veldkamp AI; van Heeswijk RP; Mulder JW; Meenhorst PL; Schreij G; van der Geest S; Lange JM; Beijnen JH; Hoetelmans RM
    J Acquir Immune Defic Syndr; 2001 Aug; 27(4):344-9. PubMed ID: 11468422
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.